Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marguerite V Evans-Galea

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Trends in Molecular Medicine|August 20, 2013
Epigenetic modifications in trinucleotide repeat diseasesMarguerite V Evans-Galea, Anthony J Hannan, Nissa Carrodus, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 15, 2007
Suppression of clonal dominance in cultured human lymphoid cells by addition of the cHS4 insulator to a lentiviral vectorMarguerite V Evans-Galea, Matthew M Wielgosz, Hideki Hanawa, et al.
Discovery Medicine|January 14, 2014
Beyond loss of frataxin: the complex molecular pathology of Friedreich ataxiaMarguerite V Evans-Galea, Paul J Lockhart, Charles A Galea, et al.
Blood Cells, Molecules & Diseases|July 3, 2007
A chromatin insulator blocks interactions between globin regulatory elements and cellular promoters in erythroid cellsByoung Y Ryu, Derek A Persons, Marguerite V Evans-Galea, et al.
Plos One|July 30, 2011
Zinc-regulated DNA binding of the yeast Zap1 zinc-responsive activatorAvery G Frey, Amanda J Bird, Marguerite V Evans-Galea, et al.
Advances in Experimental Medicine and Biology|April 6, 2013
Characterising the neuropathology and neurobehavioural phenotype in Friedreich ataxia: a systematic reviewLouise A Corben, Nellie Georgiou-Karistianis, John L Bradshaw, et al.
Blood|November 10, 2007
An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activationByoung Y Ryu, Marguerite V Evans-Galea, John T Gray, et al.
Human Gene Therapy|April 23, 2014
Cell and gene therapy for Friedreich ataxia: progress to dateMarguerite V Evans-Galea, Alice Pébay, Mirella Dottori, et al.
Neurogenetics|August 11, 2011
A novel deletion-insertion mutation identified in exon 3 of FXN in two siblings with a severe Friedreich ataxia phenotypeMarguerite V Evans-Galea, Louise A Corben, Justin Hasell, et al.
Stem Cell Reviews and Reports|December 25, 2010
Generation of induced pluripotent stem cell lines from Friedreich ataxia patientsJun Liu, Paul J Verma, Marguerite V Evans-Galea, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Trends in Molecular Medicine|August 20, 2013
Epigenetic modifications in trinucleotide repeat diseasesMarguerite V Evans-Galea, Anthony J Hannan, Nissa Carrodus, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 15, 2007
Suppression of clonal dominance in cultured human lymphoid cells by addition of the cHS4 insulator to a lentiviral vectorMarguerite V Evans-Galea, Matthew M Wielgosz, Hideki Hanawa, et al.
Discovery Medicine|January 14, 2014
Beyond loss of frataxin: the complex molecular pathology of Friedreich ataxiaMarguerite V Evans-Galea, Paul J Lockhart, Charles A Galea, et al.
Blood Cells, Molecules & Diseases|July 3, 2007
A chromatin insulator blocks interactions between globin regulatory elements and cellular promoters in erythroid cellsByoung Y Ryu, Derek A Persons, Marguerite V Evans-Galea, et al.
Plos One|July 30, 2011
Zinc-regulated DNA binding of the yeast Zap1 zinc-responsive activatorAvery G Frey, Amanda J Bird, Marguerite V Evans-Galea, et al.
Advances in Experimental Medicine and Biology|April 6, 2013
Characterising the neuropathology and neurobehavioural phenotype in Friedreich ataxia: a systematic reviewLouise A Corben, Nellie Georgiou-Karistianis, John L Bradshaw, et al.
Blood|November 10, 2007
An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activationByoung Y Ryu, Marguerite V Evans-Galea, John T Gray, et al.
Human Gene Therapy|April 23, 2014
Cell and gene therapy for Friedreich ataxia: progress to dateMarguerite V Evans-Galea, Alice Pébay, Mirella Dottori, et al.
Neurogenetics|August 11, 2011
A novel deletion-insertion mutation identified in exon 3 of FXN in two siblings with a severe Friedreich ataxia phenotypeMarguerite V Evans-Galea, Louise A Corben, Justin Hasell, et al.
Stem Cell Reviews and Reports|December 25, 2010
Generation of induced pluripotent stem cell lines from Friedreich ataxia patientsJun Liu, Paul J Verma, Marguerite V Evans-Galea, et al.
Pageof 2